PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AlzeCure demonstrates disease-modifying effects of NeuroRestore ACD856

Data from the study shows that ACD856 has a potential neuroprotective effect in a cellular mode.

AlzeCure – a company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system – has released data.

The abstract demonstrates new preclinical data with the company’s leading drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer’s disease.

The abstract – ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons – was presented by Pontus Forsell, head of research and discovery at AlzeCure, and includes new preclinical data on ACD856, the lead drug candidate in the NeuroRestore project.

Data from the study shows that ACD856 has a potential neuroprotective effect in a cellular model of nerve injury. These protective properties are believed to be mediated by an improved mitochondrial function and a protective effect on the structure of the cell, which has been demonstrated in the presented studies. Furthermore, ACD856 also increases the release of Brain-Derived Neurotrophic Factor (BDNF) from the cells, something that is believed to further enhance these positive effects.

ACD856, which is a positive modulator of mediated signalling, has been demonstrated in preclinical studies to improve cognition and memory and is ready for phase 2 clinical studies, where it is being developed primarily for the treatment of Alzheimer’s disease.

“This new data demonstrates potential disease-modifying effects of ACD856, in addition to the positive effects we have seen on memory and learning. The neuroprotective properties we see are important, as dysfunction and loss of neurons correlate strongly with impaired function in Alzheimer’s patients,” reflected Forsell.

“We are very excited about the new results with ACD856, which significantly strengthen the commercial potential of the project. It also opens up possibilities for new indication areas,” added Martin Jönsson, chief executive officer of AlzeCure.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026